Zepp Health Corporation (ZEPP) Q4 2025 Earnings Call Transcript

Understand this faster with AI
SA Transcripts158.98K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Zepp Health Corporation (ZEPP) Q4 2025 Earnings Call March 15, 2026 9:30 PM EDT Company Participants Grace Yujia Zhang - Director of Investor RelationsWang Huang - Founder, Chairman & CEOLeon Cheng Deng - Chief Financial Officer Conference Call Participants Siddharth Rajeev - Fundamental Research Corp.
Presentation Operator Ladies and gentlemen, thank you for standing by for Zepp Health Corporation's Fourth Quarter and Full Year 2025 Earnings Conference Call. [Operator Instructions] Today's call is being recorded. I will now turn the call over to your host, Ms. Grace Zhang, Director of Investor Relations for the company. Please go ahead, Grace.
Grace Yujia ZhangDirector of Investor Relations Hello, everyone, and welcome to Zepp Health Corporation's Fourth Quarter and Full Year 2025 Earnings Conference Call. The company's financial and operating results were issued in our press release at the Newswire services earlier today and are posted online. You can also view the earnings press release and slides referred to on this call by visiting the IR section of the company's website. Presenting today are Wang Huang, our Founder and Chief Executive Officer; and Leon Deng, our Chief Financial Officer. Joining us today will also have Mike Yeung Chief Operating Officer and General Manager of North America; and [ Eric Flemming ], VP of Capital Markets in North America. Before we continue, please note that today's discussion will contain forward-looking statements made under the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Forward-looking statements involve inherent risks and uncertainties. As such, the company's actual results may be materially different from the views expressed today. Further information regarding this and other risks and uncertainties are included in the company's annual report on Form 20-F for the fiscal year ended December 31, 2024, other filings as filed with the U.S. Securities and Exchange cognition. The company does not
Source Information
Discussion
0 professional contributions
Sign in to join this professional discussion.
Be the first to add a constructive contribution.
